BROADWAY FINANCIAL CORP \DE\
Current- Director 2020 to present
Skip to record
Executive record
Alpha ID: alpha:person:mary-ann-donovanVersion: public-0As of: 2026-10-04
Not yet claimed12 published Claims5 sources
- Director
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
- Professional RoleDirector at BROADWAY FINANCIAL CORP \DE\www.sec.gov
- Board membershipServes on the board of BROADWAY FINANCIAL CORP \DE\www.sec.gov
- Board roleBoard role: DirectorBYFC DEF 14A director slate
- Committee assignmentsCommittee assignments: Audit, Directors Loan, Corporate GovernanceBYFC DEF 14A director slate
Biography
Ph.D., M.D. with over 20 years of biotechnology industry experience in senior management roles at Millennium Pharmaceuticals and Incyte Pharmaceuticals. Previously served as Chief Clinical Officer of Vigilant Biosciences, Chief Medical Officer of MetaStat and Exosome Diagnostics.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Boards
Claims
Executive career
- 2024 to end not publishedExecutive title: Chief Medical Officer · Organization not publishedRENXF 10-K executive officers
- Dates not publishedExecutive title: President and Chief Executive Officer · Organization not publishedBYFC DEF 14A director slate
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
5 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
BYFC DEF 14A director slate
sec filing · Source published: May 19, 2025 · Retrieved: May 15, 2026
Supports 7 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Board role: Board role: Director · Claim reviewed: May 15, 2026
- Committee assignments: Committee assignments: Audit, Directors Loan, Corporate Governance · Claim reviewed: May 15, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Executive company: Executive at Raza Development Fund · Claim reviewed: May 15, 2026
- Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 15, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026
Open source
sec proxy · Source published: May 19, 2025 · Retrieved: Apr 28, 2026
Supports 1 claim
- Professional Role: Director at BROADWAY FINANCIAL CORP \DE\ · Claim reviewed: May 16, 2026
RNLXY 10-K executive officers
sec filing · Source published: Sep 30, 2024 · Retrieved: Jul 28, 2026
Supports 6 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Executive company: Executive at Renalytix plc · Claim reviewed: Jul 28, 2026
- Executive title: Executive title: Chief Medical Officer · Claim reviewed: Jul 28, 2026
- Other Company Role: Michael J. Donovan is also linked to Icahn School of Medicine at Mount Sinai as Professor of Experimental Pathology and Director of the Biorepository and Pathology core. · Claim reviewed: May 16, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026
RENXF 10-K executive officers
sec filing · Source published: Sep 30, 2024 · Retrieved: May 16, 2026
Supports 2 claims
- Executive company: Executive at Renalytix plc · Claim reviewed: Jul 28, 2026
- Executive title: Executive title: Chief Medical Officer · Claim reviewed: Jul 28, 2026
Open source
public source · Source published: Date unavailable · Retrieved: Date unavailable
Supports 1 claim
- Board membership: Serves on the board of BROADWAY FINANCIAL CORP \DE\ · Claim reviewed: May 16, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
corroborated
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-04
- Biography
- published
- Board service
- published
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope